Enrolled patients
N=190

Received erenumab
n=190 (100%)

Completed erenumab
n=143 (75.3%)

Discontinued erenumab, n=47 (24.7%)
- Subject request, 22 (11.6%)
- Lack of efficacy, 8 (4.2%)
- Lost to follow-up, 7 (3.7%)
- Adverse events, 5 (2.6%)
- Non-compliance, 2 (1.1%)
- Protocol deviation, 1 (0.5%)
- Pregnancy, 1 (0.5%)
- Other, 1 (0.5%)

Completed 52 Weeks of erenumab, n=143
- Patients who received 70 mg as last dose, n=77 (54%)
- Patients who received 140 mg as last dose, n=66 (46%)

Enrolled patients
N=419

Received erenumab
n=419 (100%)

Completed erenumab
n=327 (78%)

Discontinued erenumab, n=92 (22.0%)
- Subject request, 42 (10.0%)
- Lack of efficacy, 31 (7.4%)
- Adverse events, 11 (2.6%)
- Alternative therapy, 3 (0.7%)
- Lost to follow-up, 2 (0.5%)
- Sponsor decision, 1 (0.2%)
- Protocol deviation, 1 (0.2%)
- Other, 1 (0.2%)

Completed 52 Weeks of erenumab, n=326
- Patients who received 70 mg as last dose, n=189 (45%)
- Patients who received 140 mg as last dose, n=137 (33%)

Enrolled patients
N=308

Received erenumab
n=308 (100%)

Completed erenumab
n=242 (78.6%)

Discontinued erenumab, n=66 (21.4%)
- Subject request, 28 (9.1%)
- Lack of efficacy, 24 (7.8%)
- Adverse events, 8 (2.6%)
- Requirement for alternative therapy, 3 (1.0%)
- Lost to follow-up, 2 (0.6%)
- Other, 1 (0.3%)

Completed 52 Weeks of erenumab, n=241
- Patients who received 70 mg as last dose, 135 (56%)
- Patients who received 140 mg as last dose, 106 (44%)

Enrolled patients
N=218

Received erenumab
n=218 (100%)

Completed erenumab
n=165 (75.7%)

Discontinued erenumab, n=53 (24.3%)
- Subject request, 20 (9.2%)
- Lack of efficacy, 20 (9.2%)
- Adverse events, 7 (3.2%)
- Requirement for alternative therapy, 3 (1.4%)
- Lost to follow-up, 2 (0.9%)
- Other, 1 (0.5%)

Completed 52 Weeks of erenumab, n=165
- Patients who received 70 mg as last dose, n=102 (62%)
- Patients who received 140 mg as last dose, n=63 (38%)
Placebo  | Erenumab 70 mg | Erenumab 140 mg | Erenumab combined 70 mg or 140 mg (OLTP) | Erenumab 70 mg | Erenumab 140 mg

12-week DBTP | 52-week OLTP

Baseline (N=189): 6.7 (95%CI: 5.7, 7.7)

Baseline (N=305): 11.6 (95%CI: 10.8, 12.3)

Baseline (N=216): 11.8 (95%CI: 10.9, 12.7)

Last dose received during OLTP

All patients

MSM use at baseline

Placebo     Erenumab 70 mg    Erenumab 140 mg    Erenumab combined 70 mg or 140 mg (OLTP)
Figure 4. Percentage of participants with a ≥75% reduction in migraine days with headache (MMD) using the 28-day OLTP approach and the 12-week DBTP approach.

- **Never failed**
  - Placebo: 12-week DBTP: 18.1%, 28-week OLTP: 23.5%
  - Erenumab 70 mg: 12-week DBTP: 21.0%, 28-week OLTP: 28.6%
  - Erenumab 140 mg: 12-week DBTP: 24.0%, 28-week OLTP: 31.2%
  - Erenumab combined 70 mg or 140 mg (OLTP): 12-week DBTP: 23.5%, 28-week OLTP: 32.1%

- **≥2 TF**
  - Placebo: 12-week DBTP: 4.3%, 28-week OLTP: 9.0%
  - Erenumab 70 mg: 12-week DBTP: 14.1%, 28-week OLTP: 23.6%
  - Erenumab 140 mg: 12-week DBTP: 12.2%, 28-week OLTP: 19.7%
  - Erenumab combined 70 mg or 140 mg (OLTP): 12-week DBTP: 11.2%, 28-week OLTP: 18.1%

- **≥3 TF**
  - Placebo: 12-week DBTP: 3.1%, 28-week OLTP: 6.5%
  - Erenumab 70 mg: 12-week DBTP: 15.4%, 28-week OLTP: 19.8%
  - Erenumab 140 mg: 12-week DBTP: 15.1%, 28-week OLTP: 21.3%
  - Erenumab combined 70 mg or 140 mg (OLTP): 12-week DBTP: 12.9%, 28-week OLTP: 16.3%

### Last dose received during OLTP

- Placebo: 40.3%, 55.6%, 55.4%
- Erenumab 70 mg: 39.2%, 52.6%, 52.4%
- Erenumab 140 mg: 39.1%, 52.8%, 52.6%
- Erenumab combined 70 mg or 140 mg (OLTP): 39.1%, 52.8%, 52.6%
